Last reviewed · How we verify
MT027 cells suspension — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
MT027 cells suspension (MT027 cells suspension) — Suzhou Maximum Bio-tech Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MT027 cells suspension TARGET | MT027 cells suspension | Suzhou Maximum Bio-tech Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MT027 cells suspension CI watch — RSS
- MT027 cells suspension CI watch — Atom
- MT027 cells suspension CI watch — JSON
- MT027 cells suspension alone — RSS
Cite this brief
Drug Landscape (2026). MT027 cells suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/mt027-cells-suspension. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing